Vertex Pharmaceuticals Inc
VRTX Real Time Price USDRecent trades of VRTX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in VRTX holdings by institutional investors
Quarterly net insider trading by VRTX's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$1,110,000 Jan 13, 2026 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Budget/Appropriations Trade (domestic/foreign) Pharmacy Veterans
-
$1,110,000 Oct 14, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Budget/Appropriations Trade (domestic/foreign) Pharmacy
-
$1,140,000 Oct 09, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Budget/Appropriations Trade (domestic/foreign) Pharmacy
-
$1,600,000 Apr 18, 2025 Issue: Medicare/Medicaid Taxation/Internal Revenue Code Budget/Appropriations Health Issues
-
$970,000 Jan 17, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$1,000,000 Oct 18, 2024 Issue: Budget/Appropriations Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
-
$980,000 Jul 15, 2024 Issue: Medicare/Medicaid Health Issues
-
$80,000 Apr 09, 2024 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Budget/Appropriations
-
$60,000 Jan 22, 2024 Issue: Health Issues Medicare/Medicaid
-
$50,000 Jan 22, 2024 Issue: Health Issues
-
$30,000 Jan 20, 2024 Issue: Budget/Appropriations Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
-
$80,000 Jan 12, 2024 Issue: Health Issues Medicare/Medicaid
-
$890,000 Oct 19, 2023 Issue: Medicare/Medicaid Budget/Appropriations Taxation/Internal Revenue Code Health Issues
-
$630,000 Jul 19, 2023 Issue: Medicare/Medicaid Budget/Appropriations Taxation/Internal Revenue Code Health Issues
-
$370,000 Jan 18, 2023 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Taxation/Internal Revenue Code Health Issues
-
$710,000 Oct 14, 2022 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Taxation/Internal Revenue Code Health Issues
-
$520,000 Jul 19, 2022 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
-
$520,000 Apr 20, 2022 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
-
$630,000 Jan 20, 2022 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$450,000 Oct 20, 2021 Issue: Health Issues Taxation/Internal Revenue Code Budget/Appropriations Medicare/Medicaid
-
$420,000 Jul 19, 2021 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$570,000 May 21, 2021 Issue: Health Issues Medicare/Medicaid
-
$410,000 Apr 19, 2021 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$380,000 Oct 20, 2020 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$380,000 Jul 20, 2020 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$390,000 Apr 20, 2020 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$530,000 Jan 21, 2020 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
-
$310,000 Oct 21, 2019 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$310,000 Jul 22, 2019 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
-
$320,000 Apr 19, 2019 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$450,000 Jan 21, 2019 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$340,000 Oct 19, 2018 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
-
$350,000 Jul 18, 2018 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$350,000 Apr 19, 2018 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$340,000 Jan 19, 2018 Issue: Medicare/Medicaid Taxation/Internal Revenue Code Health Issues
-
$340,000 Oct 19, 2017 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
-
$560,000 Jul 20, 2017 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
-
$450,000 Apr 20, 2017 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
-
$340,000 Jan 20, 2017 Issue: Medicare/Medicaid Taxation/Internal Revenue Code Health Issues
-
$350,000 Oct 20, 2016 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
-
$440,000 Jul 20, 2016 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$210,000 Apr 20, 2016 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
-
$350,000 Jan 19, 2016 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Copyright/Patent/Trademark
-
$330,000 Oct 20, 2015 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
-
$300,000 Jul 20, 2015 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Copyright/Patent/Trademark
-
$380,000 Apr 20, 2015 Issue: Health Issues Taxation/Internal Revenue Code Copyright/Patent/Trademark Medicare/Medicaid
-
$210,000 Jan 19, 2015 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
-
$280,000 Oct 16, 2014 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$480,000 Jul 21, 2014 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$190,000 Apr 21, 2014 Issue: Medicare/Medicaid Taxation/Internal Revenue Code Copyright/Patent/Trademark Health Issues
-
$210,000 Jan 20, 2014 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
-
$210,000 Oct 21, 2013 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
-
$460,000 Jul 18, 2013 Issue: Health Issues
-
$300,000 Apr 22, 2013 Issue: Health Issues
-
$260,000 Jan 22, 2013 Issue: Budget/Appropriations Health Issues
-
$250,000 Oct 19, 2012 Issue: Health Issues Budget/Appropriations
-
$360,000 Jul 20, 2012 Issue: Budget/Appropriations Health Issues
-
$490,000 Apr 20, 2012 Issue: Health Issues Budget/Appropriations
-
$480,000 Jan 19, 2012 Issue: Health Issues Budget/Appropriations
-
$360,000 Oct 20, 2011 Issue: Health Issues Budget/Appropriations
-
$450,000 Jul 19, 2011 Issue: Health Issues
-
$460,000 Apr 20, 2011 Issue: Health Issues
-
$140,000 Jan 19, 2011 Issue: Health Issues
-
$370,000 Oct 20, 2010 Issue: Health Issues
-
$170,000 Jul 20, 2010 Issue: Health Issues
-
$300,000 Apr 20, 2010 Issue: Health Issues
-
$120,000 Jan 20, 2010 Issue: Health Issues
-
$130,000 Oct 20, 2009 Issue: Health Issues
-
$130,000 Jul 20, 2009 Issue: Health Issues
-
$180,000 Apr 20, 2009 Issue: Health Issues
-
$100,000 Jan 21, 2009 Issue: Health Issues
-
$120,000 Oct 20, 2008 Issue: Health Issues
-
$80,000 Jul 21, 2008 Issue: Health Issues
-
$80,000 Apr 21, 2008 Issue: Science/Technology Medical/Disease Research/Clinical Labs Medicare/Medicaid Copyright/Patent/Trademark Budget/Appropriations Health Issues
VRTX Estimated quarterly lobbying spending
VRTX Revenue by Segment or Geography
New VRTX patent grants
-
Patent Title: Inhibitors of influenza viruses replication May. 24, 2016
-
Patent Title: Substituted quinoxaline dna-pk inhibitors May. 17, 2016
-
Patent Title: Compounds useful as inhibitors of atr kinase May. 17, 2016
-
Patent Title: Compounds useful as inhibitors of atr kinase May. 10, 2016
-
Patent Title: Processes for producing cycloalkylcarboxamido-pyridine benzoic acids Apr. 26, 2016
-
Patent Title: Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid Apr. 19, 2016
-
Patent Title: Substituted pyrrolo[2,3-b]pyrazines as atr kinase inhibitors Apr. 12, 2016
-
Patent Title: Methods of regioselective synthesis of 2,4-disubstituted pyrimidines Mar. 29, 2016
-
Patent Title: Dna-pk inhibitors Mar. 29, 2016
-
Patent Title: Modulators of atp-binding cassette transporters Feb. 09, 2016
-
Patent Title: Automated developer for immuno-stained biological samples Feb. 02, 2016
-
Patent Title: Modulators of atp-binding cassette transporters Feb. 02, 2016
-
Patent Title: Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof Jan. 26, 2016
-
Patent Title: Modulators of atp-binding cassette transporters Dec. 22, 2015
-
Patent Title: Tri-cyclic pyrazolopyridine kinase inhibitors Nov. 24, 2015
-
Patent Title: Dosage units of 3-(6-(1-(2,2-difluorobenzo[d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid Nov. 24, 2015
-
Patent Title: Morpholine-spirocyclic piperidine amides as modulators of ion channels Nov. 10, 2015
-
Patent Title: Prodrugs of pyridone amides useful as modulators of sodium channels Oct. 20, 2015
-
Patent Title: Prodrug of an ice inhibitor Oct. 13, 2015
-
Patent Title: Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid Oct. 06, 2015
-
Patent Title: Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Sep. 22, 2015
-
Patent Title: Substituted quinoxalines as sodium channel modulators Sep. 22, 2015
-
Patent Title: Pyrazolopyridine kinase inhibitors Sep. 22, 2015
-
Patent Title: Phosphate esters of gyrase and topoisomerase inhibitors Sep. 08, 2015
-
Patent Title: Azaindoles useful as inhibitors of janus kinases Sep. 01, 2015
-
Patent Title: Amides as modulators of sodium channels Aug. 18, 2015
-
Patent Title: Azaindole derivatives as cftr modulators Aug. 11, 2015
-
Patent Title: Substituted pyrrolo[2,3-b]pyrazines as atr kinase inhibitors Aug. 04, 2015
-
Patent Title: Compounds useful as inhibitors of atr kinase Aug. 04, 2015
-
Patent Title: Modulators of atp-binding cassette transporters Jul. 28, 2015
-
Patent Title: Processes and intermediates for producing azaindoles Jul. 28, 2015
-
Patent Title: Heteroaryl derivatives as cftr modulators Jul. 14, 2015
-
Patent Title: Compounds useful as inhibitors of indoleamine 2,3-dioxygenase Jul. 07, 2015
-
Patent Title: Pyrazolopyridine kinase inhibitors Jun. 30, 2015
-
Patent Title: Compounds useful as inhibitors of atr kinase Jun. 23, 2015
-
Patent Title: Modulators of cystic fibrosis transmembrane conductance regulator Jun. 09, 2015
-
Patent Title: Inhibitors of influenza viruses replication Jun. 09, 2015
-
Patent Title: Solid forms of ( Jun. 09, 2015
-
Patent Title: Pyridone amides as modulators of sodium channels Jun. 09, 2015
-
Patent Title: Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Jun. 02, 2015
-
Patent Title: Solid forms of gyrase inhibitor (r)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pryimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1h-benzimidazol-2-yl]urea May. 26, 2015
-
Patent Title: Systems and methods for inline sampling May. 26, 2015
-
Patent Title: Process of producing cycloalkylcarboxamido-indole compounds May. 19, 2015
-
Patent Title: Processes for making compounds useful as inhibitors of atr kinase May. 19, 2015
-
Patent Title: Pyrazolopyridine kinase inhibitors May. 12, 2015
-
Patent Title: Solid forms of (r)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1h-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof Apr. 28, 2015
-
Patent Title: Processes for producing cycloalkylcarboxamido-pyridine benzoic acids Apr. 21, 2015
-
Patent Title: Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)cyclopropanecarboxamide and administration thereof Apr. 21, 2015
-
Patent Title: Modulators of atp-binding cassette transporters Apr. 21, 2015
-
Patent Title: Modulators of cystic fibrosis transmembrane conductance regulator Apr. 07, 2015
Federal grants, loans, and purchases
Estimated quarterly amount awarded to VRTX from public contracts
Recent insights relating to VRTX
Recent picks made for VRTX stock on CNBC
ETFs with the largest estimated holdings in VRTX
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $VRTX stock a Buy, Sell, or Hold?
- What is the price target for $VRTX stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $VRTX stock?
- Who owns the most shares of $VRTX stock?
- What funds own $VRTX stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view VRTX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
- Address Boston, MA
- Market Cap 124.7 billion
- Employees 6,100
- Industrial Classification Pharmaceutical Preparations
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|